quinolinic acid has been researched along with Acquired-Immune Deficiency Syndrome Dementia Complex in 37 studies
Quinolinic Acid: A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS.
pyridinedicarboxylic acid : Any member of the class of pyridines carrying two carboxy groups.
quinolinic acid : A pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of tryptophan.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Concentrations of quinolinic acid, an N-methyl-D-aspartate agonist, are often elevated for long periods of time in the cerebrospinal fluid (CSF) and brain tissue of patients with AIDS dementia complex (ADC)." | 7.70 | Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex. ( Armati, PJ; Brew, BJ; Guillemin, GJ; Kerr, SJ, 1998) |
| "Quinolinic acid (QUIN) is an end product of tryptophan, metabolized through the kynurenine pathway (KP) that can act as an endogenous brain excitotoxin when produced and released by activated macrophages/microglia, the very cells that are prominent in the pathogenesis of ADC." | 6.43 | Involvement of quinolinic acid in AIDS dementia complex. ( Brew, BJ; Guillemin, GJ; Kerr, SJ, 2005) |
| "Quinolinic acid is an agonist at the population of glutamate receptors which are sensitive to N-methyl-D-aspartate (NMDA), and kynurenic acid is an antagonist at several glutamate receptors." | 6.42 | Tryptophan metabolites and brain disorders. ( Clark, CJ; Darlington, LG; Forrest, CM; Mackay, GM; Stone, TW, 2003) |
| "AIDS-related encephalopathy, including AIDS dementia complex (ADC) and the opportunistic disease, herpes simplex encephalitis (HSE), are postulated to arise due to the release of neurotoxic products, such as quinolinic acid (QUIN), by activated microglial cells in the brain." | 3.73 | Aciclovir protects against quinolinic-acid-induced oxidative neurotoxicity. ( Daya, S; Maharaj, DS; Maharaj, H; Müller, AC, 2005) |
| " Neurotoxic factors produced from activated macrophage or microglial cells such as tumor necrosis factor-alpha (TNFalpha), gp120 and quinolinic acid have been implicated as agents for the cell death which often appears to occur by an apoptotic mechanism." | 3.71 | CPI-1189 attenuates effects of suspected neurotoxins associated with AIDS dementia: a possible role for ERK activation. ( Flitter, WD; Garland, WA; Irwin, I; Kusdra, L; Pulliam, L; Rempel, H, 2001) |
| "Activated macrophages produce quinolinic acid (QUIN), a neurotoxin, in several inflammatory brain diseases including AIDS dementia complex." | 3.71 | Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat. ( Brew, BJ; Guillemin, GJ; Kerr, S; Nath, A; Pemberton, L; Smith, DG; Smythe, GA, 2001) |
| "There is good evidence that the kynurenine pathway (KP) and one of its products, quinolinic acid (QUIN), play a role in the pathogenesis of neurological diseases, in particular AIDS dementia complex." | 3.71 | Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. ( Armati, PJ; Brew, BJ; Croitoru, J; Guillemin, GJ; Kapoor, V; Kerr, SJ; Smith, DG; Smythe, GA, 2001) |
| "Concentrations of quinolinic acid, an N-methyl-D-aspartate agonist, are often elevated for long periods of time in the cerebrospinal fluid (CSF) and brain tissue of patients with AIDS dementia complex (ADC)." | 3.70 | Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex. ( Armati, PJ; Brew, BJ; Guillemin, GJ; Kerr, SJ, 1998) |
| "HIV, soluble HLA class I (sHLA-I), quinolinic acid (QUIN), and the monokines IL-1β, IL-6, and TNF-α were measured by ELISA and PCR in brain tissue of 60 AIDS autopsies without evidence of CNS opportunistic infections." | 3.69 | Macrophage Activation Factors in the Brains of AIDS Patients. ( Achim, CL; Baldwin, M; Heyes, MP; Hilty, C; Masliah, E; Sarnacki, P; Wiley, CA, 1996) |
| "Using murine AIDS (MAIDS) as a model of retrovirus-induced immunodeficiency, the aims of this study were (1) to determine the cellular source(s) of quinolinic acid (Quin) with regard to its significance as a potential neuroexcitotoxin in AIDS dementia complex, and (2) to characterize the relationship between dendritic cell Quin immunoreactivity and the histopathological changes associated with the progression of disease." | 3.69 | Localization of quinolinic acid in the murine AIDS model of retrovirus-induced immunodeficiency: implications for neurotoxicity and dendritic cell immunopathogenesis. ( Espey, MG; Moffett, JR; Morse, HC; Namboodiri, MA; Tang, Y, 1996) |
| "We sought to determine whether the neurotoxin quinolinic acid (QUIN) was produced by macrophages or lymphocytes infected with isolates of HIV-1 with varying degrees of macrophage tropism derived from patients with varying stages of AIDS dementia complex (ADC)." | 3.69 | Quinolinic acid production is related to macrophage tropic isolates of HIV-1. ( Brew, BJ; Cooper, DA; Corbeil, J; Evans, L; Heyes, MP; Pemberton, L; Penny, R; Saito, K, 1995) |
| "Quinolinic acid (QUIN) is an end product of tryptophan, metabolized through the kynurenine pathway (KP) that can act as an endogenous brain excitotoxin when produced and released by activated macrophages/microglia, the very cells that are prominent in the pathogenesis of ADC." | 2.43 | Involvement of quinolinic acid in AIDS dementia complex. ( Brew, BJ; Guillemin, GJ; Kerr, SJ, 2005) |
| "Quinolinic acid is an agonist at the population of glutamate receptors which are sensitive to N-methyl-D-aspartate (NMDA), and kynurenic acid is an antagonist at several glutamate receptors." | 2.42 | Tryptophan metabolites and brain disorders. ( Clark, CJ; Darlington, LG; Forrest, CM; Mackay, GM; Stone, TW, 2003) |
| "Quinolinic acid (QUIN) is a product of tryptophan metabolism that can act as an endogenous brain excitotoxin when released by activated macrophages." | 1.32 | CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy. ( Heyes, M; Nilsson, A; Price, RW; Valle, M; Verotta, D, 2004) |
| "Disease progression was evaluated by virological assessment of blood and cerebral spinal fluid (CSF), CD4 T cell count in blood, and quinolinic acid levels in CSF (a surrogate marker of neuronal cell damage)." | 1.32 | HIV in central nervous system and behavioral development: an HIV-2287 macaque model of AIDS. ( Anderson, BD; Anderson, DM; Bielefeldt-Ohmann, H; Ho, RJ; Hu, SL; Kinman, LM; Leigh, J; Morton, WR; Worlein, JM, 2004) |
| "The brains from patients with HIV encephalopathy not only contained higher levels of HIV-1 DNA (cerebrum, P < ." | 1.29 | Increased human immunodeficiency virus (HIV) type 1 DNA content and quinolinic acid concentration in brain tissues from patients with HIV encephalopathy. ( Brouwers, P; Crowley, JS; Heyes, MP; Katz, DA; Kleiner, DE; Pizzo, PA; Saito, K; Sei, S; Stewart, SK, 1995) |
| "Quinolinic acid (QUIN) is a neurotoxin implicated in the neurologic deficits associated with human immunodeficiency virus type 1 (HIV-1) infection." | 1.29 | Quinolinic acid in the cerebrospinal fluid of children with symptomatic human immunodeficiency virus type 1 disease: relationships to clinical status and therapeutic response. ( Brouwers, P; Heyes, MP; Markey, SP; Moss, HA; Pizzo, PA; Poplack, DG; Wolters, PL, 1993) |
| "Quinolinic acid (QUIN) is an endogenous neurotoxic N-methyl-D-aspartate agonist that may contribute to the pathogenesis of HIV-associated neurologic disease." | 1.29 | Quinolinic acid levels in a murine retrovirus-induced immunodeficiency syndrome. ( Hartley, JW; Heyes, MP; Layar, R; Morse, HC; Paul, IA; Saito, K; Sei, Y; Skolnick, P, 1996) |
| "Quinolinic acid (QUIN) is a tryptophan metabolite which has been found to be an excitotoxin in rats, although its toxicity in humans is unknown." | 1.29 | Neurocytotoxity of quinolinic acid in human brain cultures. ( Armati, PJ; Brew, BJ; Kerr, SJ, 1995) |
| "Quinolinic acid (QUIN) is an neurotoxic N-methyl-D-aspartate receptor agonist and an L-tryptophan metabolite of the kynurenine pathway." | 1.28 | Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients. ( Bhalla, RB; Brew, BJ; Der, M; Heyes, MP; Lee, K; Markey, SP; Price, RW; Quearry, BJ; Saito, K, 1992) |
| "Quinolinic acid is an "excitotoxic" metabolite and an agonist of N-methyl-D-aspartate receptors." | 1.28 | Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. ( Brew, BJ; Heyes, MP; Keilp, J; Martin, A; Mouradian, MM; Price, RW; Sadler, AE; Salazar, AM; Sidtis, JJ; Yergey, JA, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 25 (67.57) | 18.2507 |
| 2000's | 10 (27.03) | 29.6817 |
| 2010's | 2 (5.41) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, AM | 1 |
| Croteau, D | 1 |
| Ellis, RJ | 1 |
| Rosario, D | 1 |
| Potter, M | 1 |
| Guillemin, GJ | 5 |
| Brew, BJ | 9 |
| Woods, SP | 1 |
| Letendre, SL | 1 |
| Nair, MP | 1 |
| Samikkannu, T | 1 |
| Stone, TW | 1 |
| Mackay, GM | 1 |
| Forrest, CM | 1 |
| Clark, CJ | 1 |
| Darlington, LG | 1 |
| Valle, M | 1 |
| Price, RW | 5 |
| Nilsson, A | 1 |
| Heyes, M | 2 |
| Verotta, D | 1 |
| Kinman, LM | 1 |
| Worlein, JM | 1 |
| Leigh, J | 1 |
| Bielefeldt-Ohmann, H | 1 |
| Anderson, DM | 1 |
| Hu, SL | 1 |
| Morton, WR | 1 |
| Anderson, BD | 1 |
| Ho, RJ | 1 |
| Kerr, SJ | 4 |
| Müller, AC | 1 |
| Maharaj, H | 1 |
| Maharaj, DS | 1 |
| Daya, S | 1 |
| Ganzella, M | 1 |
| Jardim, FM | 1 |
| Boeck, CR | 1 |
| Vendite, D | 1 |
| Achim, CL | 3 |
| Masliah, E | 1 |
| Heyes, MP | 12 |
| Sarnacki, P | 1 |
| Hilty, C | 1 |
| Baldwin, M | 1 |
| Wiley, CA | 5 |
| Sei, S | 1 |
| Saito, K | 4 |
| Stewart, SK | 1 |
| Crowley, JS | 1 |
| Brouwers, P | 2 |
| Kleiner, DE | 1 |
| Katz, DA | 1 |
| Pizzo, PA | 2 |
| Black, R | 1 |
| Sager, P | 1 |
| Lipton, SA | 1 |
| Yeh, M | 1 |
| Dreyer, EB | 1 |
| Moss, HA | 1 |
| Wolters, PL | 1 |
| Poplack, DG | 1 |
| Markey, SP | 4 |
| Sei, Y | 1 |
| Paul, IA | 1 |
| Layar, R | 1 |
| Hartley, JW | 1 |
| Morse, HC | 2 |
| Skolnick, P | 1 |
| Yoshioka, M | 1 |
| Bradley, WG | 1 |
| Shapshak, P | 1 |
| Nagano, I | 1 |
| Stewart, RV | 1 |
| Xin, KQ | 1 |
| Srivastava, AK | 1 |
| Nakamura, S | 1 |
| Nottet, HS | 1 |
| Flanagan, EM | 1 |
| Flanagan, CR | 1 |
| Gelbard, HA | 1 |
| Gendelman, HE | 3 |
| Reinhard, JF | 1 |
| Espey, MG | 1 |
| Tang, Y | 1 |
| Moffett, JR | 1 |
| Namboodiri, MA | 1 |
| Corbeil, J | 1 |
| Pemberton, L | 2 |
| Evans, L | 1 |
| Penny, R | 1 |
| Cooper, DA | 1 |
| Armati, PJ | 3 |
| Zheng, J | 2 |
| Coulter, CL | 1 |
| Ghorpade, A | 1 |
| Che, M | 1 |
| Thylin, M | 2 |
| Rubocki, R | 1 |
| Persidsky, Y | 1 |
| Hahn, F | 1 |
| Reinhard, J | 1 |
| Swindells, S | 1 |
| Staprans, S | 1 |
| Marlowe, N | 1 |
| Glidden, D | 1 |
| Novakovic-Agopian, T | 1 |
| Grant, RM | 1 |
| Aweeka, F | 1 |
| Deeks, S | 1 |
| Xiong, H | 1 |
| Zeng, YC | 1 |
| Chao, CC | 1 |
| Hu, S | 1 |
| Gekker, G | 1 |
| Lokensgard, JR | 1 |
| Peterson, PK | 1 |
| Pulliam, L | 1 |
| Irwin, I | 1 |
| Kusdra, L | 1 |
| Rempel, H | 1 |
| Flitter, WD | 1 |
| Garland, WA | 1 |
| Smith, DG | 2 |
| Kerr, S | 1 |
| Nath, A | 1 |
| Smythe, GA | 2 |
| Kapoor, V | 1 |
| Croitoru, J | 1 |
| Martin, A | 3 |
| Salazar, AM | 2 |
| Kampen, DL | 1 |
| Williams, J | 1 |
| Law, WA | 1 |
| Coats, ME | 1 |
| Quearry, BJ | 1 |
| Lee, K | 1 |
| Bhalla, RB | 2 |
| Der, M | 1 |
| Schrier, RD | 1 |
| McCutchan, JA | 1 |
| Grant, I | 1 |
| Schwarcz, R | 1 |
| Du, F | 1 |
| Sidtis, JJ | 1 |
| Yergey, JA | 1 |
| Mouradian, MM | 1 |
| Sadler, AE | 1 |
| Keilp, J | 1 |
| Brew, B | 1 |
| Salazar, A | 1 |
| Cotton, P | 1 |
7 reviews available for quinolinic acid and Acquired-Immune Deficiency Syndrome Dementia Complex
| Article | Year |
|---|---|
Differential regulation of neurotoxin in HIV clades: role of cocaine and methamphetamine.
Topics: Acquired Immunodeficiency Syndrome; AIDS Dementia Complex; Arachidonic Acid; Central Nervous System | 2012 |
Tryptophan metabolites and brain disorders.
Topics: AIDS Dementia Complex; Brain Diseases; Central Nervous System Diseases; Humans; Huntington Disease; | 2003 |
Involvement of quinolinic acid in AIDS dementia complex.
Topics: AIDS Dementia Complex; Animals; Humans; Quinolinic Acid | 2005 |
Quantitative neuropathologic assessment of HIV-1 encephalitis.
Topics: AIDS Dementia Complex; Atrophy; Brain; Brain Chemistry; Cell Count; Encephalitis, Viral; Giant Cells | 1995 |
Update on current models of HIV-related neuronal injury: platelet-activating factor, arachidonic acid and nitric oxide.
Topics: AIDS Dementia Complex; Arachidonic Acid; Cytokines; HIV Envelope Protein gp120; HIV Infections; Huma | 1994 |
Role of immune activation and cytokine expression in HIV-1-associated neurologic diseases.
Topics: AIDS Dementia Complex; Apoptosis; Cell Adhesion; Cytokines; Endothelium, Vascular; Glutamic Acid; HI | 1995 |
Quinolinic acid and kynurenic acid in the mammalian brain.
Topics: 3-Hydroxyanthranilate 3,4-Dioxygenase; AIDS Dementia Complex; Animals; Aspartic Acid; Biological Tra | 1991 |
30 other studies available for quinolinic acid and Acquired-Immune Deficiency Syndrome Dementia Complex
| Article | Year |
|---|---|
HIV, prospective memory, and cerebrospinal fluid concentrations of quinolinic acid and phosphorylated Tau.
Topics: Adult; AIDS Dementia Complex; Biomarkers; Female; Humans; Male; Memory Disorders; Memory, Episodic; | 2018 |
CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy.
Topics: Adult; AIDS Dementia Complex; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Cr | 2004 |
HIV in central nervous system and behavioral development: an HIV-2287 macaque model of AIDS.
Topics: AIDS Dementia Complex; Analysis of Variance; Animals; Behavior, Animal; Cognition; Disease Progressi | 2004 |
Aciclovir protects against quinolinic-acid-induced oxidative neurotoxicity.
Topics: Acyclovir; AIDS Dementia Complex; Animals; Antiviral Agents; Brain; Hippocampus; Lipid Peroxidation; | 2005 |
Time course of oxidative events in the hippocampus following intracerebroventricular infusion of quinolinic acid in mice.
Topics: AIDS Dementia Complex; Animals; Antioxidants; Cells, Cultured; Disease Models, Animal; Encephalitis; | 2006 |
| Macrophage Activation Factors in the Brains of AIDS Patients.
Topics: Acquired Immunodeficiency Syndrome; AIDS Dementia Complex; AIDS-Related Opportunistic Infections; Br | 1996 |
Increased human immunodeficiency virus (HIV) type 1 DNA content and quinolinic acid concentration in brain tissues from patients with HIV encephalopathy.
Topics: Adolescent; Adult; AIDS Dementia Complex; AIDS-Related Opportunistic Infections; Base Sequence; Brai | 1995 |
Summary of workshop contributions. Third Workshop on NeuroAIDS.
Topics: Adult; AIDS Dementia Complex; Animals; Blood-Brain Barrier; Child; Cytokines; Cytopathogenic Effect, | 1994 |
Quinolinic acid in the cerebrospinal fluid of children with symptomatic human immunodeficiency virus type 1 disease: relationships to clinical status and therapeutic response.
Topics: Acquired Immunodeficiency Syndrome; AIDS Dementia Complex; Analysis of Variance; Child; Child, Presc | 1993 |
Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains.
Topics: Adult; AIDS Dementia Complex; Autopsy; Brain; Cytokines; Granulocyte-Macrophage Colony-Stimulating F | 1993 |
Quinolinic acid levels in a murine retrovirus-induced immunodeficiency syndrome.
Topics: AIDS Dementia Complex; Animals; Brain Chemistry; Cytokines; Defective Viruses; Disease Models, Anima | 1996 |
The regulation of quinolinic acid in human immunodeficiency virus-infected monocytes.
Topics: AIDS Dementia Complex; Astrocytes; Brain; HIV-1; Humans; Macrophages; Monocytes; Quinolinic Acid; Ti | 1996 |
Localization of quinolinic acid in the murine AIDS model of retrovirus-induced immunodeficiency: implications for neurotoxicity and dendritic cell immunopathogenesis.
Topics: AIDS Dementia Complex; Animals; Brain Chemistry; Dendritic Cells; Disease Models, Animal; Female; Li | 1996 |
Quinolinic acid and neurodegeneration in AIDS.
Topics: AIDS Dementia Complex; Humans; Nerve Degeneration; Neurotoxins; Quinolinic Acid | 1995 |
Quinolinic acid production is related to macrophage tropic isolates of HIV-1.
Topics: AIDS Dementia Complex; Carbon Radioisotopes; HIV-1; Humans; Lymphocytes; Macrophages; Neurotoxins; Q | 1995 |
Neurocytotoxity of quinolinic acid in human brain cultures.
Topics: AIDS Dementia Complex; Astrocytes; Brain; Cell Death; Cells, Cultured; Dose-Response Relationship, D | 1995 |
Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex.
Topics: AIDS Dementia Complex; Cells, Cultured; Dose-Response Relationship, Drug; Humans; Image Processing, | 1998 |
Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia.
Topics: Adult; AIDS Dementia Complex; Anti-HIV Agents; Atrophy; Brain; Female; Humans; Ibuprofen; Indinavir; | 1998 |
Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection.
Topics: Adult; AIDS Dementia Complex; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV | 1999 |
Soluble HIV-1 infected macrophage secretory products mediate blockade of long-term potentiation: a mechanism for cognitive dysfunction in HIV-1-associated dementia.
Topics: AIDS Dementia Complex; Animals; Cells, Cultured; Culture Media; Hippocampus; HIV-1; Humans; In Vitro | 1999 |
U50,488 protection against HIV-1-related neurotoxicity: involvement of quinolinic acid suppression.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; AIDS Demen | 2000 |
CPI-1189 attenuates effects of suspected neurotoxins associated with AIDS dementia: a possible role for ERK activation.
Topics: AIDS Dementia Complex; Apoptosis; Brain; Butanes; Cells, Cultured; Culture Media, Conditioned; Enzym | 2001 |
Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat.
Topics: AIDS Dementia Complex; Enzyme Induction; Gene Products, nef; Gene Products, tat; HIV Envelope Protei | 2001 |
Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection.
Topics: AIDS Dementia Complex; Astrocytes; Brain; Cells, Cultured; Cytokines; Enzymes; Fetus; Humans; Kynure | 2001 |
Progressive slowing of reaction time and increasing cerebrospinal fluid concentrations of quinolinic acid in HIV-infected individuals.
Topics: Adult; AIDS Dementia Complex; Anxiety Disorders; Depressive Disorder; Female; HIV Seropositivity; Hu | 1992 |
Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients.
Topics: Acquired Immunodeficiency Syndrome; AIDS Dementia Complex; beta 2-Microglobulin; Biopterins; Blood-B | 1992 |
Relationship of cerebrospinal fluid immune activation associated factors to HIV encephalitis.
Topics: Adult; AIDS Dementia Complex; AIDS-Related Opportunistic Infections; beta 2-Microglobulin; Biomarker | 1992 |
Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status.
Topics: AIDS Dementia Complex; Convulsants; HIV Infections; HIV-1; Humans; Neurotoxins; Quinolinic Acid; Qui | 1991 |
Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; AIDS Dementia Complex; Extracellular Space; Humans; Quinolinic A | 1991 |
AIDS dementia may be linked to metabolite of tryptophan.
Topics: AIDS Dementia Complex; Animals; Humans; Neurotoxins; Pyridines; Quinolinic Acid; Quinolinic Acids; T | 1990 |